glp-1 agonist joint pain Glucagon-Like Peptide-1 Receptor Agonists in Osteoarthritis: From Clinical Promise to Preclinical Evidence glp 1 and joint pain
Description
As the pharmaceutical industry continues to grow, conversations around drug safety, responsible medication use, and regulatory vigilance are becoming more important than ever
September 9, 2025
In clinical trials, the obesity-focused oral version requires 70 times more active pharmaceutical ingredient (API) than the subcutaneous alternative (175 mg per week vs
LaFrance J
Given that these results were coming from a randomised, double-blind clinical trial, the Parkinsons community got rather excited about them ( Click here to read a previous SoPD post about this particular trial)
However, waiting passively can mean weeks or months of discomfort
